checkAd
    Startseite > Aktien > Biodexa Pharmaceuticals > Nachrichten
    Biodexa Pharmaceuticals Aktie
    0,0452
     
    EUR
    -5,83 %
    -0,0028 EUR
    Letzter Kurs 04.07.23 Frankfurt
    0,0452
     
    EUR
    5.000 STK
    Geldkurs 04.07.23
    0,0752
     
    EUR
    5.000 STK
    Briefkurs 04.07.23
    ISIN: US59564R6099 · WKN: A3D7BE · SYM: 5MP1 · Großbritannien

    Neueste Nachrichten

    Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises
    22.05.24 · globenewswire · Biodexa Pharmaceuticals
    Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa’s Newly-licensed eRapa in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting
    21.05.24 · globenewswire · Biodexa Pharmaceuticals
    Posting of Annual Report & Notice of AGM - Total Voting Rights
    15.05.24 · globenewswire · Biodexa Pharmaceuticals
    Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting
    30.04.24 · globenewswire · Biodexa Pharmaceuticals
    Biodexa Enters Into Exclusive License to eRapa, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)
    26.04.24 · globenewswire · Biodexa Pharmaceuticals
    Preliminary Results for the Year Ended 31 December 2023
    19.04.24 · globenewswire · Biodexa Pharmaceuticals
    Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update
    23.02.24 · globenewswire · Biodexa Pharmaceuticals
    Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients
    08.02.24 · globenewswire · Biodexa Pharmaceuticals
    Biodexa Announces Allowance of U.S. Patent Covering Tolimidone
    07.02.24 · globenewswire · Biodexa Pharmaceuticals
    Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024
    22.01.24 · globenewswire · Biodexa Pharmaceuticals
    Biodexa Appoints Ann Merchant to the Board of Directors
    29.12.23 · globenewswire · Biodexa Pharmaceuticals
    Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option
    21.12.23 · globenewswire · Biodexa Pharmaceuticals